Worldwide Clinical Trials and Science 37 Partner to Advance Agile Clinical Trials and Accelerate Study Timelines - Seite 2

About Worldwide Clinical Trials
Worldwide Clinical Trials is a global midsize contract research organization (CRO) that provides top-performing preclinical and Phase I-IV clinical development services to the biotechnology and pharmaceutical industries.

Founded in 1986 by physicians committed to advancing medical science, our full-service clinical experience ranges from early phase and bioanalytical sciences through late phase studies, post approval and real-world evidence. Major therapeutic areas of focus include cardiovascular, metabolic, neuroscience, oncology and rare diseases. With infrastructure spanning 60 countries and offices in North and South America, Eastern and Western Europe, Russia and Asia, Worldwide is powered by its more than 2,600 employee experts.

For more information please visit www.worldwide.com or connect with us on Twitter, LinkedIn, Facebook, and Instagram.

About Science 37
Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 Agile Clinical Trial Operating System (OS) supports today’s more agile clinical research designs with its full stack, end-to-end technology platform and specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators and connected devices. Configurable to enable almost any study type, the Science 37 OS enables up to 15x faster enrollment, 28% better retention and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation and data harmonization. For more information, visit https://www.science37.com.

MEDIA INQUIRIES:

Worldwide Clinical Trials
Karen Hagens
VP, Global Corporate Communications
[e-mail]

Science 37
Margie Kooman
VP, Marketing & Communications
[e-mail]

INVESTOR RELATIONS:
Caroline Paul
Gilmartin
[e-mail]